Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives

Guang-xia Chen1,*
Shu Zhang2–4,*
Xiao-hua He1
Shi-yu Liu1
Chao Ma2–4
Xiao-Ping Zou2–4

1Department of Gastroenterology, First People’s Hospital of Xuzhou, Xuzhou, Jiangsu Province, People’s Republic of China; 2Department of Gastroenterology, Drum Tower Hospital, 3Medical School of Nanjing University, 4Jiangsu Clinical Medical Center of Digestive Disease, Nanjing, People’s Republic of China

*These authors have contributed equally to the paper

Abstract: Gene therapy has promised to be a highly effective antitumor treatment by introducing a tumor suppressor gene or the abrogation of an oncogene. Among the potential therapeutic transgenes, the tumor suppressor gene p53 serves as an attractive target. Restoration of wild-type p53 function in tumors can be achieved by introduction of an intact complementary deoxyribonucleic acid copy of the p53 gene using a suitable viral vector, in most cases an adenoviral vector (Adp53). Preclinical in vitro and in vivo studies have shown that Adp53 triggers a dramatic tumor regression response in various cancers. These viruses are engineered to lack certain early proteins and are thus replication defective, including Gendicine, SCH-58500, and Advexin. Several types of tumor-specific p53-expressing conditionally replicating adenovirus vectors (known as replication-competent CRAdp53 vectors) have been developed, such as ONYX 015, AdDelta24-p53, SG600-p53, OBP-702, and H101. Various clinical trials have been conducted to investigate the safety and efficiency of these adenoviral vectors. In this review we will talk about the biological mechanisms, clinical utility, and therapeutic potentials of the replication-deficient Adp53-based and replication-competent CRAdp53-based gene therapy.

Keywords: adenovirus, Adp53, CRAdp53

Introduction

Because cancer is an acquired genetic disorder, gene therapy promises to be a highly effective antitumor treatment for inducing cell death via introduction of a therapeutic tumor suppressor gene or the abrogation of an oncogene, which is tailored to the precise genetic structure of each tumor and therefore produces low systemic toxicity.1,2 Among the potential therapeutic transgenes, the tumor suppressor gene p53 is an attractive target because of its function as the “guardian of the genome” by inducing cell cycle arrest, senescence, and apoptosis in response to oncogene activation, deoxyribonucleic acid (DNA) damage, and other stress signals.3 Inactivation of p53 function is a common feature of human tumors that often correlates with increased malignancy, poor patient survival, and resistance to chemotherapy and/or radiotherapy.4–6 Evidence generated over the past decade has demonstrated that the p53 tumor suppressor is the most frequently altered gene in over 50% of all types of human cancers, with more than 25,000 mutations currently reported in the International Agency for Research on Cancer TP53 database.7 These findings suggest that p53 has potent and critical roles in suppressing malignant progression, making restoration of wild-type p53 gene function a promising antitumor strategy.

Restoration of wild-type p53 function in tumors can be achieved by introduction of an intact complementary DNA copy of the p53 gene using a suitable viral vector, in
most cases an adenoviral vector (Adp53). This gene replacement therapy to transfer p53 gene directly into cancer cells has been demonstrated to suppress tumor growth because ectopic expression of exogenous p53 gene efficiently induces cell death and cell-cycle arrest in a variety of p53-inactivated tumor cells, with evidence for bystander effects in some cases. An advantage of the adenovirus delivery system is that it does not result in integration of the vector DNA into the host cells. Preclinical in vitro and in vivo studies have shown that Adp53 triggers a dramatic tumor regression response in various cancers, including head and neck cancer, lung cancer, colorectal cancer, ovarian cancer, bladder cancer, prostate cancer, and esophageal cancer. These viruses are engineered to lack certain early proteins and are thus replication defective. With this method thousands of patients have received Adp53-based gene therapies in clinical trials, mostly in the USA and the People’s Republic of China. Gendicine is the world’s first Adp53-based gene therapy product approved by a government agency for clinical use. This recombinant human Adp53 injection developed by Shenzhen SiBiono Gene Tech (SiBiono; Shenzhen, People’s Republic of China) was approved by the State Food and Drug Administration of the People’s Republic of China (SFDA) on October 16, 2003 for the treatment of head and neck squamous cell carcinoma, and was formally launched in April 2004. Other Adp53 vectors such as SCH-58500 (CANJII, Inc., San Diego, CA, USA) and Advexin (INGN-201; Introgen Therapeutics, Inc. Austin, TX, USA) have been developed and used in various clinical trials. Regarding the low transduction rate of p53 gene introduction via Adp53 vector, several types of tumor-specific p53-expressing conditionally replicating adenovirus vectors (known as replication-competent CRAp53 vectors) have been developed, such as ONYX 015, AdDelta24-p53, SG600-p53, OBP-702, and H101 (Table 1). In this review, we will talk about the biological mechanisms, clinical utility, and therapeutic potentials of the replication-deficient Adp53-based and replication-competent CRAp53-based gene therapy.

### Table 1 Clinical studies of p53 cancer gene therapy using Adp53 and CRAp53 vectors

<table>
<thead>
<tr>
<th>Type of adenoviral vector</th>
<th>Recombinant adenovirus</th>
<th>Cancer types</th>
</tr>
</thead>
<tbody>
<tr>
<td>Replication-deficient Adp53 vectors</td>
<td>Gendicine</td>
<td>SCCHN, NSCLC, HCC</td>
</tr>
<tr>
<td></td>
<td>Advexin</td>
<td>SCCHN</td>
</tr>
<tr>
<td></td>
<td>SCH-58500</td>
<td>NSCLC</td>
</tr>
<tr>
<td>Replication-competent CRAp53 vectors</td>
<td>ONYX 015</td>
<td>SCCHN, colorectal cancer, pancreatic carcinoma, malignant glioma, sarcomas</td>
</tr>
<tr>
<td></td>
<td>H101</td>
<td>SCCHN</td>
</tr>
<tr>
<td></td>
<td>AdDelta24-p53</td>
<td>/</td>
</tr>
<tr>
<td></td>
<td>SG600-p53</td>
<td>/</td>
</tr>
<tr>
<td></td>
<td>OBP-702</td>
<td>/</td>
</tr>
</tbody>
</table>

Note: ‘/’ indicates no data.

Abbreviations: SCCHN, squamous cell carcinoma of the head and neck.

### Molecular mechanism

As p53 activity is impaired or defective in most human cancers, the obvious goal of Adp53 vectors is to reestablish the growth-inhibitory functions of p53 in cancer cells. Cell death pathways, such as apoptosis and autophagy, induced by p53 expression are mainly involved in the suppression of tumor initiation and development. A great variety of genes are now identified as p53 target genes, whose protein products induce multiple outcomes such as apoptosis (eg, Bax, DR5, PUMA, and Noxa), cell cycle arrest (eg, p21 and GADD45), and autophagy (eg, DRAM) (Figure 1). Several studies indicate that delivery of Adp53 induces dramatic cell death via apoptosis and cell cycle arrest in human glioma and glioblastoma cells, preceded by elevation in the levels of the p21 and Bax. OBP-702-mediated p53 transactivation demonstrates its therapeutic potential by inducing dual apoptotic and autophagic cell death pathways via regulation of DRAM, an

However, the inability of this approach to infect every cell in the tumor with virus has drawn people’s attention. Problems of effective repeated dosing because of the presence of a host antibody to adenovirus that reduces their infectivity, also exist. Bystander effect is therefore very important in explaining Adp53-mediated inhibition of tumor progression. For example, Adp53 infection markedly inhibits the expression of an angiogenic factor, vascular endothelial growth factor, and increases the expression of an antiangiogenic factor, brain-specific angiogenesis inhibitor 1, resulting in reduced neovascularization and tumor growth of adjacent nontransduced cells in vivo. Immunological mechanisms involving natural killer cells play an important role in the bystander effect involving Adp53 gene therapy for ovarian cancer. Additionally, overexpression of CD95L by the wild-type p53 gene transfer induces neutrophil infiltration into human colorectal tumors. These findings suggest that Adp53-mediated p53 overexpression is a promising antitumor therapy because angiogenesis is inhibited and immune responses are involved within tumor tissues.

**Clinical utility of the replication-deficient Adp53-based gene therapy Gendicine**

Many clinical trials using Adp53-based therapies have been performed all over the world involving thousands of patients. As the first approved commercial Adp53 vector product, Gendicine, a recombinant human serotype 5 adenovirus in which the E1 region is replaced by a human wild-type p53 expression cassette, has been tested in Phase I to IV clinical trials in models of human gastric cancer through inhibiting MDM2-mediated p53 degradation. In a Phase I clinical trial in 2003, Gendicine was used for treating 12 patients with advanced laryngeal cancer, with an average clinical course of 41 months. There was no patient relapse for more than 5 years after Gendicine treatment. In comparison, the 3-year relapse rate for patients with advanced laryngeal cancer receiving surgery alone is generally about 30%. Three Phase II/III clinical trials enrolling patients with squamous cell carcinomas of head and neck (SCCHN) demonstrated that Gendicine in combination with radiotherapy showed obvious synergistic effects. An extended follow-up on a subset of nasopharyngeal carcinoma patients, in which 82 patients were randomized to receive Adp53 injection and radiotherapy (GTRT; n=42) or radiotherapy alone (RT; n=40), showed that complete response rate in the GTRT group was observed at 2.73 times that of the RT group (66.7% vs 24.4%). Upregulation of p21/WAF1 and Bax and downregulation of vascular endothelial growth factor were observed in postinjection tumor biopsy. Adp53 significantly increased the 5-year locoregional tumor control rate by 25.3% for patients treated with irradiation alone (P=0.002).

In a Phase II trial of adenovirus p53 gene replacement for non-small-cell lung cancer (NSCLC), Adp53 was administered to 21 patients with advanced NSCLC and produced little toxicity, along with potentially useful clinical responses. Time to disease progression in the indicator lesion treated with Adp53 appears to be enhanced by higher doses of vector and concomitant cisplatin therapy. A nonrandomized, two-armed clinical trial enrolled 58 patients with advanced NSCLC, of which 19 received a combination therapy of bronchial arterial infusion and Gendicine (the combo group), while the remaining 39 were treated with only bronchial arterial infusion (the control group). The overall response rates were 47.3% and 38.4% for the combo and control group, respectively (P>0.05). Patients in the combo group had a longer time to progression than those in the control group (a median 7.75 vs 5.5 months, P=0.018). But the combination treatment did not lead to better survival.

In another Phase II trial, 40 patients diagnosed with NSCLC who had been treated with chemotherapy were recruited for this study. Nineteen of them were assigned to the DOCp53 group, receiving transtracheal Adp53 injection on Day 1 and Day 8, as well as docetaxel on Day 2, and 21 patients were assigned to the DOC group, receiving docetaxel alone on Day 1. Disappointingly, for patients with relapsed NSCLC, transtracheal injection of Adp53 in addition to docetaxel did not improve overall survival or efficacy.
In 2005, a case report showed a 23-year-old patient with recurrent hepatocellular carcinoma (HCC) who was treated with Gendicine combined with transcatheter arterial chemoembolization (TACE). A total of 3×10^{12} virus particles of Gendicine were infused via the hepatic artery. Four days later, the virus particles superselectively embolized the patient’s hepatic arteries with 5-fluorouracil, vinorelbine, and iodized oil. Seven months later, the patient had normal liver function and was in good clinical health with no further recurrence. A clinical study in the People’s Republic of China enrolled 150 patients, of whom 68 patients were treated with the Gendicine-TACE combination, and 82 patients were treated with TACE alone as a control group. The response rates were 67.6% in the Gendicine (GT)-TACE group and 51.2% in the TACE-alone group (P<0.05). The 6-month survival rate was 76.5% in the GT-TACE group and only 23.2% in the control group (P<0.01), showing that Gendicine in combination with TACE is effective for the treatment of HCC to enhance patients’ survival rate. In another study, 40 patients with diagnosed primary HCC were randomly treated by fractionated stereotactic radiotherapy (fSRT) group alone or Gendicine combined with fSRT (combined group). These patients belonged to a group lower than Grade B on Child-Pugh classification with no extrahepatic metastasis. During 44 months of follow-up, the 1-year survival rates of the fSRT and combined groups were 70.0% and 90.0% respectively (P=0.081), suggesting the potential efficacy of Gendicine combined with fSRT in treating patients with HCC.

**Ad vexin**

Another Adp53 vector, Ad vexin, has not yet been approved by the Food and Drug Administration and the company developing it has closed, although some remarkable clinical cases have been reported. A Phase I/II study of Ad vexin enrolled ten patients with chemoradiation-resistant advanced esophageal squamous cell carcinoma. Intratumoral injections of Ad vexin were administered on Days 1 and 3 for up to five cycles. Local tumor responses revealed stable disease in nine cases and progressive disease in one case. In another Phase II study, 13 patients with squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx received surgery and perioperative Ad vexin injections in the primary tumor bed and the ipsilateral neck. In addition, three patients received injections in the contralateral neck. This therapy presented to be technically feasible, and the estimate of 1-year progression-free survival was 92%. Additional Phase III trials are warranted to enhance our understanding on the efficacy of Ad vexin in increasing the survival rates of patients with various malignancies.

**SCH-58500**

Twenty-five patients with nonresectable NSCLC were enrolled in an open-label, multicenter Phase II study of three cycles of regimen A, carboplatin plus paclitaxel, or regimen B, cisplatin plus vinorelbine in combination with intratumoral injection of 7.5×10^{12} particles of SCH-58500. There was no significant difference between the response rate of lesions treated with p53 gene therapy combined with chemotherapy (52%) and lesions treated with chemotherapy alone (48%). There was no survival difference between the two groups, and the median survival of the cohort was 10.5 months (1-year survival, 44%). Conclusively the authors suggested that intratumoral SCH-58500 therapy appeared to provide no additional benefit in patients receiving chemotherapy for advanced NSCLC. Several other Phase I/II clinical trials have demonstrated that SCH-58500 therapy is a feasible and safe treatment for ovarian and bladder cancer. However, we are not able to conclude whether SCH-58500 has potential benefit on survival and tumor response rates of patients with various cancers.

**Safety and immune responses of the replication-deficient Adp53 in clinical use**

Although some self-limited fever cases have been reported, so far no severe adverse effects have been found in patients treated with Gendicine and other replication-deficient Adp53 vectors. No related fatalities have been reported. Data from the clinical trials have demonstrated that replication-deficient Adp53-based gene therapy is well tolerated and safe for clinical use.

The adenoviral vector is known to induce a strong immune response in patients, which is manifested by the development of self-limited fevers. Although considered to be a side effect in clinical use, fever also reflects the effectiveness and benefits of Adp53 in mobilizing the body’s immune systems.

**Therapeutic potential and clinical utility of the replication-competent CRAdp53-based gene therapy**

The low transduction rate of p53 gene via Adp53 is a major problem that must be solved to improve the clinical outcomes of patients with various advanced cancers. The adenovirus E1B 55K protein binds and blocks p53, thus preventing
p53-induced cell death and apoptosis, and allowing viral replication and production of viral progeny. Therefore, these tumor-specific, replication-competent CRAdp53 vectors have been developed in which the promoters of cancer-related genes are used to enhance E1-dependent virus replication in a tumor-dependent manner. As a consequence, CRAdp53 is superior to Adp53 vectors in inducing higher p53 expression and stronger antitumor effects through induction of cell death and apoptosis. Here we discuss the therapeutic potential of several types of CRAdp53 vectors (eg, ONYX 015, AdDelta24-p53, SG600-p53, OBP-301, OBP-702, and H101) in anticancer p53 gene therapies.

ONYX 015

Exploiting a virus with a known deletion in the E1B region of its genome, the Onyx company developed and brought into clinical trial the oncolytic ONYX 015 virus. ONYX 015 is currently the most prominent and clinically evaluated CRAdp53 vector which can only proliferate effectively in p53 mutant but not p53 wild-type cells. However, this concept remains controversial. Some studies have demonstrated that wild-type p53 is necessary for the activation of the rapid adenovirus-induced cell death, or that ONYX 015 replication in human tumor cells does not correlate with the status of p53. The current view indicates that ONYX 015 oncolytic selectivity seems to be defined not purely by p53 status but rather by the state of the stress response in the target cell.

In an in vivo study, ONYX 015 was proved to inhibit tumor growth, and its antitumor efficacy combined with chemotherapy was significantly greater than either agent alone. RNA interference-mediated knockdown of p21 enhances antitumor efficacy of ONYX 015 in human cancer cells.

Numerous clinical trials have been conducted among patients with various advanced cancers. In a Phase II trial, 37 patients with recurrent head and neck carcinoma were enrolled. Significant tumor regression (>50%) was observed in 21% of evaluable patients, with no toxicity to injected normal peritumoral tissues. p53 mutant tumors were significantly more likely to undergo ONYX 015-induced necrosis than p53 wild-type tumors. Another Phase II trial enrolled 40 patients with SCCHN, receiving ONYX 015 at a dose of 20 particles via intratumoral injection for either 5 consecutive days (standard, 30) or twice daily for two consecutive weeks (hyperfractionated, ten) during a 21-day cycle. Standard treatment resulted in 14% partial to complete regression, while hyperfractionated treatment resulted in 10% complete response, indicating that ONYX 015 was a safe treatment for SCCHN with evidence of modest antitumoral activity. ONYX 015 combined with chemotherapy is more efficient than chemotherapy alone for patients with recurrent SCCHN. ONYX 015 may also benefit patients with refractory metastatic colorectal cancer who have failed prior treatment with 5-fluorouracil (FU)/leucovorin by hepatic artery infusion. For patients with unresectable pancreatic carcinoma, ONYX 015 injection into tumors via endoscopic ultrasound by the transgastric route with prophylactic antibiotics was feasible and generally well tolerated either alone or in combination with gemcitabine. Two of the 21 patients had partial regression of the injected tumor, two had minor responses, and six had stable disease. Other Phase I/II trials showed that patients with advanced sarcomas, hepatobiliary tumors, and malignant gliomas could tolerate ONYX 015, alone or with other chemotherapy, well and safely. They also provided some evidence of antitumor activity for ONYX 015. However, the clinical effect of ONYX 015 has varied greatly, and there are still many patients responding poorly. The reason may have to do with the fact that E1B 55K has other functions than binding p53, including viral RNA export and inhibition of host protein synthesis, as previously described. The actual effects of ONYX 015 in treating various tumors need to be further investigated in preclinical experiments and clinical trials.

H101

H101 is a recombinant human type 5 adenovirus with a total deletion of E1B 55K gene and an additional deletion of 78.3–85.8 μm gene segment in the E3 region, making it a CRAdp53 vector similar to ONYX 015. Deleted segments of E3 region may enhance the safety of the product. The oncolytic anticancer effect has been confirmed by various clinical trials, although the exact mechanism is not clear.

A Phase II clinical study conducted in the People’s Republic of China enrolled 50 patients with malignant tumors in multiple centers, receiving H101 therapy 0.5 mL, 50 viral particles per day for 5 consecutive days every 3 weeks, combined with routine chemotherapy. The overall response rate was 30.4% among 46 evaluable cases, with well-tolerated toxicities. A Phase III randomized clinical trial compared effects and toxicities of intratumoral H101 injection combined with cisplatin plus 5-fluorouracil (PF) regimen versus PF regimen alone in treating patients with head and neck or esophagus squamous cell cancer. Among 123 evaluable patients, the overall response rate of PF plus H101 group was 78.8%, and of PF alone group was 39.6%. Differences of response rates between the two groups were significant (P=0.000). As a result, intratumoral injection of H101 showed efficacy in treating patients with squamous cell cancer.
cancer of the head and neck or esophagus. Chinese government regulators (SFDA) approved H101 especially for advanced nasopharyngeal carcinoma in combination with cisplatin and 5-FU chemotherapy in 2005. Recent in vitro studies demonstrate that the combination of H101 and dacarbazine exerts a synergistic antitumor effect to unveil melanoma cells without enhanced toxicity to normal cells via a type of cell cycle block, reflecting H101 a promising agent in treating melanoma.67

Other CRAdp53 vectors
AdDelta24-p53 is a CRAdp53 vector in which the Rb protein-binding CR2 domain (24 bp) of the E1A region is deleted and the p53 expression cassette under the regulation of simian virus 40 early promoter is inserted into the E3 region. This virus expresses enhanced oncolytic potency on 80% of tested human cancer cell lines. AdDelta24-p53 can also kill most malignant glioma cell lines, inhibit glioma growth in animals, and prolong animals surviving in an in vivo study. However, this vector in combination with radiotherapy causes an increase in the percentage of apoptotic glioma cells and a significant enhancement of the number of mice demonstrating tumor regression as well as long-term survival.69 However, a small number of cancer cell lines expressing high levels of the major negative p53 regulator MDM2 respond poorly to AdDelta24-p53. So a novel CRAdp53 vector AdDelta24-p53(14/19) encoding a p53 variant incapable of binding to MDM2 has been developed, exhibiting approximately ten times more effectively than AdDelta24-p53 in killing cancer cell lines with high levels of MDM2 expression. The finding suggests that inhibition of MDM2-dependent p53 negative regulation serves to be a promising treatment for increasing the antitumor efficacy of CRAdp53 gene therapy.

Another CRAdp53 vector SG600-p53 has been engineered, in which the E1A gene with a deletion of 24 nucleotides within CR2 region is controlled under the human telomerase reverse transcriptase promoter, and the E1B gene is directed by the hypoxia response element, whereas the p53 gene is controlled by the cytomegalovirus promoter. The tumor-selective replication of this vector and its antitumor efficacy are characterized in several tumor cell lines in vitro and in xenograft models of human non-small-cell lung cancer (NSCLC) in nude mice. Vincristine might increase the antitumor efficacy of SG600 against retinoblastoma cells. Recently, SG635-p53 has been developed in which the Ad5 fiber is replaced with a chimeric Ad5/35 fiber. This novel vector produces more progeny viruses, mediates a higher level of transgenic expression, and shows a markedly enhanced antitumor effect in HCC cells compared with SG600-p53. OBP-301 is an adenovirus 5 vector in which the human telomerase reverse transcriptase promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site. OBP-301 induces tumor-selective oncolysis and antitumor effect in a telomerase-dependent manner in various cancer cells; eg, head and neck cancer, human bone and soft tissue sarcomas, and prostate cancer. This vector injected into the primary tumor might be effective in purging micrometastasis from regional lymph nodes in an orthotopic colorectal cancer model. OBP-301 enhances the sensitivity of various cancers to chemotherapy; eg, lung cancer, ovarian cancer. Then OBP-702 is engineered by combining OBP-301 and wild-type p53 gene. OBP-702 suppresses the viability of both OBP-301-sensitive and OBP-301-resistant human cancer cells, inhibits tumor growth in mice models, and induces more profound cell apoptosis and autophagy compared to monotherapy with OBP-301 or Adp53. This effect is probably achieved through E1A-dependent p21 and MDM2 suppression.

Although basic research has demonstrated the antitumor potential of these CRAdp53 vectors, we lack evidence from clinical trials to determine the safety, feasibility, and clinical efficacy of these vectors.

Conclusion
As a common tumor suppressing gene, p53 serves as a very important gene therapy target. Thus, adenovirus-mediated p53 cancer gene therapy develops and proves to be a promising antitumor strategy to restore the wild-type p53 function, inducing profound p53-mediated cell death pathways. In this review, we discuss the molecular mechanisms and preclinical and clinical studies of Adp53 and CRAdp53 gene therapy in many types of human cancers. Phase I/II/III clinical trials of some replication-deficient Adp53 vectors have been carried out in patients with diverse cancers, demonstrating that Adp53 gene therapy is well tolerated, feasible, and exerts promising antitumor effects. Regarding the low transduction rate and insufficient delivering system of these Adp53 vectors in many patients, more replication-competent CRAdp53 vectors have been engineered. However, clinical studies fail to provide enough evidence of safety and antitumor efficacy for these CRAdp53 vectors. Until now, only Gendicine and H101 have been approved by the government (SFDA), and these vectors, both Adp53 and CRAdp53, are not widely used for patients around the world. The exact mechanisms and clinical antitumor effect of these vectors need to be further explored. More safe and efficient delivering systems should be developed.
Acknowledgments
This work was funded by the National Natural Science Foundation of China (Grant No 81101814, 81272742).

Disclosure
The authors declare no conflicts of interest in this work.

References


